Monopar Therapeutics Inc AI Stock Analysis
Want to see MNPR full AI Analyst Report?
Monopar Therapeutics Inc (MNPR) AI Stock Analysis
Monopar Therapeutics Inc
(NASDAQ:MNPR)
The score is driven primarily by weak financial performance (no revenue, sustained losses, and materially worse TTM cash burn) despite a low-debt balance sheet. Technicals add pressure given bearish momentum and the price sitting below key moving averages. Valuation is constrained by negative earnings and the absence of a dividend yield.
Monopar Therapeutics Inc (MNPR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $476.34M
- Dividend Yield
- ―
- Average Volume (3M)
- 152.28K
- Price to Earnings (P/E)
- -27.2
- Beta (1Y)
- 1.54
- Revenue Growth
- ―
- EPS Growth
- 25.00%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Monopar Therapeutics Inc Business Overview & Revenue Model
Company Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNP...
How the Company Makes Money
Monopar Therapeutics does not have a stable, product-based commercial revenue stream because it is a clinical-stage drug developer and, as such, typically does not sell approved drugs. As a result, its ability to generate cash is primarily driven by...
Monopar Therapeutics Inc Financial Statement Overview
Summary
Pre-revenue profile with persistent losses and a sharp TTM deterioration in earnings and cash burn are major risks. Offsetting this, leverage is very low and the equity base is relatively supportive, reducing near-term solvency pressure but not eliminating funding needs.
Income Statement
6Very NegativeBalance Sheet
78PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -20.60M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income | -20.60M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
Balance Sheet | ||||||
| Total Assets | 130.25M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Cash, Cash Equivalents and Short-Term Investments | 129.45M | 140.40M | 60.21M | 7.27M | 13.12M | 20.30M |
| Total Debt | 357.26K | 154.92K | 0 | 0 | 8,408 | 0 |
| Total Liabilities | 3.18M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Stockholders Equity | 127.07M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
Cash Flow | ||||||
| Free Cash Flow | -3.26B | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Operating Cash Flow | -3.26B | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Investing Cash Flow | 4.05B | -63.45M | -14.34M | 4.93M | -4.92M | 0 |
| Financing Cash Flow | -647.39M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M |
Monopar Therapeutics Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MNPR, the sentiment is Negative. The current price of 69.00 is below the 20-day moving average (MA) of 71.11, below the 50-day MA of 79.19, and below the 200-day MA of 77.43, indicating a bearish trend. The MACD of -2.12 indicates Negative momentum. The RSI at 42.23 is Neutral, neither overbought nor oversold. The STOCH value of 23.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MNPR.
Monopar Therapeutics Inc Risk Analysis
Monopar Therapeutics Inc disclosed 76 risk factors in its most recent earnings report. Monopar Therapeutics Inc reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksMonopar Therapeutics Inc Peers Comparison
Overall Rating
REPL55Neutral
KURA48Neutral
ORIC48Neutral
CADL46Neutral
CTMX46Neutral
MNPR46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $1.82B | -6.89 | -157.78% | ― | ― | 19.12% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 48Neutral | $675.31M | -2.23 | -336.24% | ― | -23.76% | -33.09% | |
| 48Neutral | $800.27M | -5.27 | -40.99% | ― | ― | 15.37% | |
| 46Neutral | $402.43M | -3.47 | -88.58% | ― | ― | -171.31% | |
| 46Neutral | $446.91M | -4.54 | -33.97% | ― | -87.66% | -210.45% | |
| 46Neutral | $476.34M | -27.24 | -15.52% | ― | ― | 25.00% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| MNPR | Monopar Therapeutics Inc | 69.00 | -23.75 | -25.61% | |
| CTMX | CytomX Therapeutics Inc. | 2.03 | -1.94 | -48.87% | |
| KURA | Kura Oncology | 6.91 | -4.82 | -41.09% | |
| REPL | Replimune Group | 19.07 | 9.68 | 103.09% | |
| ORIC | Oric Pharmaceuticals Inc | 7.36 | -4.43 | -37.57% | |
| CADL | Candel Therapeutics, Inc. | 5.04 | 0.51 | 11.26% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
